MK-2206, an AKT inhibitor that specifically targets the PI3K-AKT-mTOR pathway, has shown promising therapeutic potential in the management of urothelial BCs, offering a targeted approach to disrupting cancer cell survival pathways (24). Here, AKT1 is linked to cancer.